HYPEREOSINOPHILIC SYNDROME (HES)

Clinical trials for HYPEREOSINOPHILIC SYNDROME (HES) explained in plain language.

Never miss a new study

Get alerted when new HYPEREOSINOPHILIC SYNDROME (HES) trials appear

Sign up with your email to follow new studies for HYPEREOSINOPHILIC SYNDROME (HES), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Life-Changing drug access extended for asthma and rare disease patients

Disease control Not yet recruiting

This study provides continued access to the medication benralizumab (Fasenra) for people with asthma, EGPA, or HES who completed a previous clinical trial and are still benefiting from the treatment. It aims to monitor the long-term safety of the drug while allowing participants …

Matched conditions: HYPEREOSINOPHILIC SYNDROME (HES)

Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control

Last updated Mar 24, 2026 12:02 UTC

HYPEREOSINOPHILIC SYNDROME (HES)

Get alerted when new HYPEREOSINOPHILIC SYNDROME (HES) trials appear

Life-Changing drug access extended for asthma and rare disease patients